The generic development timeline in Europe: how long each step takes and when the exclusivity clocks bite

Timed backwards from a date

A generic programme does not start when a company has an idea; it starts when a date is close enough. The date is whichever ends last of the reference product’s data and market protection, its patents and its SPC, in the markets that matter. Everything below is scheduled so that the product is approved, priced and in stock on that day, and the programme’s cost is lost if the date moves the wrong way.

The steps, for an oral solid dose

Active ingredient (six to twelve months). Find a supplier whose manufacturing is documented in a form the regulator accepts, a European certificate of suitability or an active substance master file, audit it, and secure a second source if the first also supplies the originator. For an old molecule this is a purchase; for a product coming off patent for the first time, the API suppliers are themselves racing, and quality and supply security decide the field.

Formulation and pilot studies (six to twelve months). Develop a formulation that matches the reference product’s dissolution and is manufacturable at scale, then a small pilot bioequivalence study to confirm it is on target before the expensive one.

Pivotal bioequivalence (three to six months). A crossover study in healthy volunteers against the reference product bought in an EU market, with the pharmacokinetic parameters inside the accepted limits. Modified-release, narrow-therapeutic-index and highly variable products need more, sometimes several studies.

Stability and the dossier (in parallel, six to twelve months). Stability data on registration batches, at least six months at filing with more accumulating during assessment, and the common technical document assembled.

All of this is protected from patent infringement by the Bolar exemption, which covers the studies and trials needed to obtain an authorisation. Making and holding commercial stock is not covered, with the narrow exception of the SPC manufacturing waiver’s six-month stockpiling allowance.

Application and approval (twelve to eighteen months). The application may be submitted only once eight years have passed since the reference product’s first EU authorisation. Most generics use the decentralised procedure: a reference member state assesses, the others comment, the procedure runs 210 days on paper and longer with clock stops, and each state then issues its licence in a short national phase. The UK’s MHRA runs its own assessment, with recognition routes that lean on an EU decision.

Pricing, reimbursement and listing (zero to twelve months). Nothing in the UK; a listing cycle in Germany; a price and reimbursement decision in France, Spain and Italy; a tender in the Nordics, the Netherlands and most hospital markets. The launch date is the exclusivity date only where this step is done.

Launch (at year ten, or eleven, or the SPC date). With licences, prices, packs and stock in each market on the day.

The sum

For a straightforward oral generic, two to three years from decision to approval, plus the wait for the market to open, with out-of-pocket costs in the low single-digit millions of euros for a programme covering a handful of markets. Complex generics (inhalers, injectables, long-acting formulations, products needing clinical endpoint studies) take four to six years and cost multiples of that; biosimilars take six to nine years and an order of magnitude more, which is why they start around year two of the reference product’s life.

Where the clocks bite

• Year eight is the earliest filing date and therefore the deadline for the dossier. Miss it and the approval, not the exclusivity, becomes the gate.
• Year ten (eleven) is the earliest sale, if the patents and SPC have already gone. For most new compounds they have not, and the SPC date, years later, is the real target; the programme is then timed to that date and the regulatory clocks are irrelevant.
• The SPC date moves. A paediatric extension granted late adds six months; a revocation brings the date forward by years; the notification-date rule adds days. A programme timed to the register date is retimed whenever the register changes, which is the single best argument for watching it continuously.

Why it matters, by role

For a launch planner, the diagram is the Gantt chart: start dates run backwards from the target, and the target is a register entry that must be checked quarterly.

For a parallel trader or buyer, the timeline explains what you can infer from public signals: a generic authorisation appearing in a national register means the product is a year or two from the open; a Drug Tariff or Lauer-Taxe listing means days.

For an originator or licensor, it says when competitor programmes must have started to meet your date, which is a guide to how many will be there on the day.

MPA Search holds the dates the programme is timed to: first EU authorisation, patent expiry, SPC and paediatric extension per country, with the licences that show who has filed.